Life Systems, Inc., Formerly Bio-Preserve International Corporation: Corporate Update.Business Editors REDMOND, Wash.--(BUSINESS WIRE)--Nov. 28, 2000 Bio-Preserve International Corporation is pleased to announce completion of its corporate reorganization. The Company's business purpose remains the same. Reflecting this restructuring, the Company has recapitalized, elected a new Board of Directors and has changed its name to Life Systems, Inc. The Company will be trading under stock symbol LIFS LIFS London International Film School LIFS Lower Internal Facility Shields LIFS Lund Immigrant Association on the OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB pink sheets. All Bio-Preserve International Corporation shareholders holding stock as of record date November 27, 2000 will be issued new certificates directly from the Company's transfer agent, First American First American may refer to:
Life Systems, Inc. is engaged in the manufacture and sale of the LifeSustainer(TM) 1000, an advanced organ perfusion workstation. The Company is also developing the LifeSustainer(TM) 2000, and advanced human organ transporter to be used in clinical transplant applications. The LifeSustainer series brings together the diverse components used for isolated organ perfusion into compact, effective user-friendly devices. Such devices are used in biomedical research Biomedical research (or experimental medicine), in general simply known as medical research, is the basic research or applied research conducted to aid the body of knowledge in the field of medicine. , to preserve human organs for transplant and for therapeutic treatment of isolated organs. The company also provides organ preservation and perfusion research services on a contract basis to pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. in using isolated for drug discovery and other types of biomedical research. This news release contains "forward-looking statements" as defined by Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions contained within that section. These statements are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially, including but not limited to future product, market and technology development, future acquisitions and divestments, obtaining regulatory approval when required, price and product competition, dependence on new product development, customer demand for our products and services and other factors. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion